AMGNAmgenRunning, no new patients
Myasthenia Gravis Inebilizumab Trial
Myasthenia Gravis
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 238 (final count)
- Started
- Oct 15, 2020
- Main results expected
- May 28, 2024
- Fully finished
- Jun 7, 2029
- Results posted
- Mar 10, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population
Measured over: Baseline and Week 26
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04524273 · record last updated 2026-05-15 · checked 2026-11-09 15:47 UTC